Indaptus Therapeutics, Inc. (INDP)
INDP moved a median of 0.00% 30 minutes after news, and -0.50% by the close. How INDP actually reacts to news — the realized, point-in-time move the market made, measured across 229 labeled events over the last three years with zero look-ahead.
INDP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 186 |
| 30-min | 0.00% | 50% | 213 |
| 60-min | 0.00% | 49% | 223 |
| to close | -0.50% | 47% | 229 |
| Middle 50% of INDP reactions | -2.19% to +2.98% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 229 |
Half of all Indaptus Therapeutics, Inc. news events land between -2.19% and +2.98% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when INDP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INDP's baseline. Nothing else.
Recent INDP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-8 Indaptus Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.19% | +3.19% | |
| Form 8-K Indaptus Therapeutics, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -5.79% | -19.86% | |
| Form 8-K Indaptus Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +5.08% | +28.00% | |
| Form 8-K/A Indaptus Therapeutics, For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +3.10% | +43.41% | |
| Form 8-K Indaptus Therapeutics, For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +3.10% | +43.41% | |
| Form 8-K Indaptus Therapeutics, For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +1.36% | +2.73% | |
| Form EFFECT Indaptus Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +4.13% | +4.59% | |
| Form S-3 Indaptus Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -7.00% | -6.39% | |
| Form 10-Q Indaptus Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.92% | +3.92% | |
| Form 8-K Indaptus Therapeutics, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | +3.92% | |
| Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.92% | +3.92% | |
| Form EFFECT Indaptus Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -1.60% | |
| Form DEF 14A Indaptus Therapeutics, For: Jul 16 | SEC filing · Form DEF | SEC EDGAR | — | +2.85% | |
| Form S-3 Indaptus Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +1.76% | -10.26% | |
| Form 8-K Indaptus Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -2.23% | -8.94% | |
| Form PRE 14A Indaptus Therapeutics, For: Jun 22 | SEC filing · Form PRE | SEC EDGAR | +2.22% | +3.06% | |
| Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders | Press release | GlobeNewswire | +0.22% | -13.33% | |
| Form 8-K Indaptus Therapeutics, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +10.23% | -40.34% | |
| Form 10-Q Indaptus Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -9.66% | |
| Form 8-K Indaptus Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | — | -9.66% | |
| Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -9.66% | |
| Form 8-K/A Indaptus Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +3.13% | +7.19% | |
| Form 8-K Indaptus Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | — | -7.08% | |
| Form 8-K Indaptus Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -0.61% | +7.36% | |
| Form 8-K Indaptus Therapeutics, For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.53% | |
| Form 10-K Indaptus Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -8.54% | -6.03% | |
| Form 8-K Indaptus Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | — | +7.14% | |
| Form 8-K Indaptus Therapeutics, For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -6.76% | -6.78% | |
| Form DEFA14A Indaptus Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -6.76% | -6.78% | |
| Form DEF 14A Indaptus Therapeutics, For: Jan 21 | SEC filing · Form DEF | SEC EDGAR | — | +5.32% | |
| Form 8-K Indaptus Therapeutics, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | -7.99% | |
| Form 8-K Indaptus Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | +5.03% | |
| Form PRE 14A Indaptus Therapeutics, For: Dec 31 | SEC filing · Form PRE | SEC EDGAR | -1.67% | +5.03% | |
| Form 8-K Indaptus Therapeutics, For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | -4.54% | |
| Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar | Press release | GlobeNewswire | +9.84% | +24.20% | |
| Form 8-K Indaptus Therapeutics, For: Dec 22 | SEC filing · Form 8-K | SEC EDGAR | -3.34% | -11.37% | |
| Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit | Press release | GlobeNewswire | +0.00% | -14.02% | |
| Form 10-Q Indaptus Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.97% | +5.86% | |
| Form 8-K Indaptus Therapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +6.97% | +5.86% | |
| Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +6.97% | +5.86% | |
| Form 8-K Indaptus Therapeutics, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | -17.43% | |
| Indaptus Therapeutics Provides Clinical Update | Press release | GlobeNewswire | +0.66% | -17.43% | |
| Form S-1/A Indaptus Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -2.62% | -5.59% | |
| Form S-1 Indaptus Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -2.18% | |
| Indaptus Therapeutics to Present at the H.C. Wainwright 27?? Annual Global Investment Conference | Press release | GlobeNewswire | -0.17% | -10.89% | |
| Form EFFECT Indaptus Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.51% | -1.38% | |
| Form 10-Q Indaptus Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.66% | +7.79% | |
| Form 8-K Indaptus Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +7.79% | |
| Form S-3 Indaptus Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +2.69% | -1.76% | |
| Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.66% | +7.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INDP section they belong to.
Where else INDP is measured.
INDP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Indaptus Therapeutics, Inc.'s median reaction calculated?
Every labeled INDP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 229 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of INDP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INDP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.